A 21 mg dose
Nicoderm CQ patch applied to the left arm
A nicotine patch is a transdermal patch that releases nicotine into the body through the skin. It is used as an aid in nicotine replacement therapy (NRT), a process for smoking cessation. The first published study of the pharmacokinetics of a transdermal nicotine patch in humans was authored by Jed E. Rose, Ph.D., Murray E. Jarvik, M.D., Ph.D. and K. Daniel Rose, M.D., in the journal Drug and Alcohol Dependence (vol. 13, pp.209-213, 1984). This was followed by publication of results of a study of smokers showing that a transdermal nicotine patch reduced craving for cigarettes (Rose JE, Herskovic JE, Trilling Y and Jarvik ME, Clinical Pharmacology and Therapeutics, vol. 38, pp. 450-456, 1985). The University of California filed a patent application in April, 1985 that was granted in 1991 (U.S. Patent #4,920,989). However, a competing patent application, filed by Dr. Frank T. Etscorn III, was issued on July 1, 1986 (U.S. Patent #4,597,961). Subsequently, the U.S. Patent Office declared an interference action and, on September 29, 1993, issued a priority decision in favor of the Rose et al. patent.
[edit] Issues
[edit] Efficacy
Dozens of clinical trials have shown that the patch approximately doubles success rates over placebo treatment.[1]
[edit] Alternate uses
Nicotine patches are under study to help relieve the symptoms of post-surgical pain.[2]
[edit] See also
[edit] References
- ^ Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009
- ^ Nicotine Patch Decreases Post Surgical Pain
-solution.jpg)
